MAP4K3 Inhibitors Targeting Dimer Interface
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current small molecule kinase inhibitors targeting MAP4K3 face challenges due to potential toxicities from off-target inhibition of other MAPK family members, particularly when targeting the ATP binding pocket, limiting their development for therapeutic use.
Innovation Solution
Identification of specific small molecule inhibitors through in silico screening and medicinal chemistry, leveraging the dimer interface of MAP4K3 to disrupt enzyme activity, with compounds like those in Formula I structures that effectively inhibit MAP4K3 phosphorylation and promote TFEB nuclear localization and autophagy flux.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ATP-site small molecule kinase inhibitors are used to target MAP4K3, then enzyme inhibition is achieved, but off-target inhibition of other MAPK family members occurs causing toxicity
Solution Approach 1:
The patent applies local quality by designing inhibitors that target a specific local region (dimer interface) of the MAP4K3 protein rather than the general ATP binding pocket. This localized targeting allows selective inhibition of MAP4K3 without affecting other MAPK family members, thereby achieving enzyme inhibition efficacy while avoiding off-target toxicity.
Solution Approach 2:
The patent segments the inhibition strategy by focusing on the dimer interface region specifically, separating this from the ATP binding pocket. This segmentation allows the inhibitor to bind at a distinct location that is unique to MAP4K3's dimeric structure, enabling selective targeting without cross-reactivity with other kinases.
2Object-affected harmful factors
If inhibitors targeting the dimer interface are designed, then off-target effects are reduced, but structural complexity of the inhibitor increases
Solution Approach 1:
The patent applies dimensionality change by transitioning from targeting the ATP binding pocket (two-dimensional planar interaction) to targeting the dimer interface (three-dimensional spatial arrangement). This dimensional shift allows exploitation of the unique 3D geometry of the dimer interface, enabling selective binding through spatial constraints rather than increased molecular complexity.
Data Source
AI summary
The disclosure provides for small molecule inhibitors of the regulatory kinase MAP4K3, and methods of use thereof.